Open AccessPB2032: MAGNETISMM‐9: AN OPEN‐LABEL, MULTICENTER, NON‐RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Author(s) -
Fonseca R.,
Kuroda J.,
Ishida T.,
Popat R.,
Huang J. S.,
Yver A.,
Vandendries E.,
Elmeliegy M.,
Ma W. D.,
Sborov D. W.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850960.38950.59
Subject(s) - medicine , multiple myeloma , cytokine release syndrome , regimen , refractory (planetary science) , adverse effect , gastroenterology , clinical trial , phases of clinical research , oncology , immunotherapy , cancer , chimeric antigen receptor , physics , astrobiology